High regional variability of HIV, HCV and injecting risks among people who inject drugs in Poland: Comparing a cross-sectional bio-behavioural study with case-based surveillance

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Rosińska, Magdalena ^a   Sierosławski, Janusz ^b   Wiessing, Lucas ^c  

^a NATIONAL INSTITUTE OF HYGIENE   (Poland)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^c EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

Author keywords

HCV; HIV; Injecting drug use; People who inject drugs; Prevalence; Surveillance

Indexed keywords

AMPHETAMINE; DIAMORPHINE; HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; OPIATE;

ADULT; ARTICLE; BLOODSTREAM INFECTION; CROSS-SECTIONAL STUDY; DISEASE SURVEILLANCE; DRUG ABUSE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; POLAND; RISK ASSESSMENT; RISK FACTOR; SEROPREVALENCE; SOCIOECONOMICS; TREND STUDY; VIRUS TRANSMISSION; ADVERSE EFFECTS; CASE CONTROL STUDY; DRUG USE; HEALTH SURVEY; HEPACIVIRUS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; PREVALENCE; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; VIROLOGY; YOUNG ADULT;

ADULT; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DRUG USERS; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; MALE; NEEDLE SHARING; POLAND; POPULATION SURVEILLANCE; PREVALENCE; RISK FACTORS; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84924047133     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-0828-9     Document Type: Article

References (45)

1. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. 2007 Reference Group to the UNon HIV and Injecting Drug Use:HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375:1014-28.
2. McCoy CB, Rodriguez F. Global overview of injection drug use and HIV infection. Lancet. 2005;365:1008-9.
3. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571-83.
4. European Centre for Disease Prevention and Control/WHO RegionalOffice for Europe. HIV/AIDS surveillance in Europe 2012. Stockholm: European Centre for Disease Prevention and Control; 2013.
5. Hedrich D, Kalamara E, Sfetcu O, Pharris A, Noor A, Wiessing L, et al. Human immunodeficiency virus among people who inject drugs: is riskincreasing in Europe? Euro Surveill. 2013;18:20648.
6. Fotiou A, Micha K, Paraskevis D, Terzidou M, Malliori M, Hatzakis A. HIV outbreak among injecting drug users in Greece. An updated brief report for the EMCDDA on the recent outbreak of HIV infections among drug injectors in Greece. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2012 [http://www.emcdda.europa.eu/publications/ad-hoc/2012/greece-hiv-update]
7. Botescu A, Abagiu A, Mardarescu M, Ursan M. HIV/AIDS among injecting drug users in Romania. Report of a recent outbreak and initial response policies. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2012 [http://www.emcdda.europa.eu/publications/ad-hoc/2012/romania-hiv-update]
8. European Monitoring Centre for Drugs and Drug Addiction and European Centre for Disease Prevention and Control. HIV in injecting drug users in the EU/EEA, following a reported increase of cases in Greece and Romania. Lisbon: European Monitoring Centre for Drugs and Drug Addiction and European Centre for Disease Prevention and Control; 2012 [http://www.emcdda.europa.eu/attachements.cfm/att_146511_EN_emcdda-ecdc-2012-riskassessment.pdf]
9. Pharris A, Wiessing L, Sfetcu O, Hedrich D, Botescu A, Fotiou A, et al. Human immunodeficiency virus in injecting drug users in Europe following a reported increase of cases in Greece and Romania, 2011. Euro Surveill. 2011, 16, pii: 20032. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20032.
10. Committee on the Prevention of HIV Infection Among Injecting Drug Users in High-Risk Countries. Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence. Washington, DC, USA: National Academy of Sciences. [http://www.nap.edu/catalog/11731/preventing-hiv-infection-among-injecting-drug-users-in-high-risk-countries]
11. Gowing LR, Farrell M, Bornemann R, Sullivan LE, Ali RL. Methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med. 2006;21:193-5.
12. Metzger DS, Navaline H, Woody GE. Drug abuse treatment as AIDS prevention. Public Health Rep. 1998;113 Suppl 1:97-106.
13. Sullivan LE, Moore BA, Chawarski MC, Pantalon MV, Barry D, O'Connor PG, et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat. 2008;35:87-92.
14. van den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M, Amsterdam C. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction. 2007;102:1454-62.
15. Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106:1978-88.
16. Dutta A, Wirtz AL, Baral S, Beyrer C, Cleghorn FR. Key harm reduction interventions and their impact on the reduction of risky behavior and HIV incidence among people who inject drugs in low-income and middle-income countries. Curr Opin HIV AIDS. 2012;7:362-8.
17. Wiessing L, Likatavicius G, Klempová D, Hedrich D, Nardone A, Griffiths P. Associations Between Availability and Coverage of HIV-Prevention Measures and Subsequent Incidence of Diagnosed HIV Infection Among Injection Drug Users. Am J Public Health. 2009;99:1049-52.
18. Uusküla A, Raag M, Folch C, Prasad L, Karnite A, van Veen MG, et al. Self-reported testing, HIV status and associated risk behaviours among people who inject drugs in Europe - important differences between East and West. AIDS 2014. In press.
19. Sierosławski, J. Estimation of prevalence of problem drug use and analysis of the patterns of drug use and associated problems [In Polish]. [http://www.kbpn.gov.pl/portal?id=459814]
20. Malczewski A, Struzik M. (eds). Annual Report 2012 Poland: Drug Situation. [http://www.kbpn.gov.pl/portal?id=111319]
21. Malczewski A (ed.):Annual Report 2010 Poland: Drug Situation. [http://www.cinn.gov.pl/portal?id=105923]
22. Reintjes R, Wiessing L. 2nd-generation HIV surveillance and injecting drug use: uncovering the epidemiological ice-berg. Int J Public Health. 2007;52:166-72.
23. World Health Organization and UNAIDS. Guidelines for second generation HIV surveillance: The next decade. Geneva: WHO and UNAIDS; 2000. [http://www.who.int/hiv/pub/surveillance/en/cds_edc_2000_5.pdf]
24. Spina A, Eramova I, Lazarus JV. Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey. BMC Infect Dis. 2014;14 Suppl 6:S15.
25. Kretzschmar M, Zhang W, Mikolajczyk RT, Wang L, Sun X, Kraemer A, et al. Regional differences in HIV prevalence among drug users in China: potential for future spread of HIV? BMC Infect Dis. 2008;8:108.
26. Vickerman P, Martin NK, Hickman M. Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings-implications for intervention impact. Drug Alcohol Depend. 2012;123:122-31.
27. Czerwinski M, McNutt LA, DeHovitz JA, Zielinski A, Rosinska M. Refining HIV risk: the modifying effects of youth, gender and education among people who inject drugs in Poland. PLoS One. 2013;8:e68018. doi:10.1371/journal.pone.0068018.
28. Van Kerckhoven I, Vercauteren G, Piot P, van der Groen G. Comparative evaluation of 36 commercial assays for detecting antibodies to HIV. Bull World Health Organ. 1991;69:753-60.
29. Pawlotsky JM. Diagnostic tests for hepatitis C. J Hepatol. 1999;31 Suppl 1:71-9.
30. Little RJA, Rubin DB. Statistical Analysis with Missing Data. New York: J. Wiley & Sons; 1987.
31. Royston P. Multiple imputation of missing values: further update of ice, with an emphasis on interval censoring. Stata J. 2007;7:445-64.
32. Malczewski A, Struzik M, Jaskiewicz A. First national survey low-thresholds clients and services in 2008. Study report. [http://www.cinn.gov.pl/portal?id=166055]
33. Lardelli P, de la Fuente L, Alonso JM, López R, Bravo MJ, Delgado-Rodríguez M. Geographical variations in the prevalence of HIV infection among drug users receiving ambulatory treatment in Spain. Int J Epidemiol. 1993;22:306-14.
34. Lorvick J, Kral AH, Seal K, Gee L, Edlin BR. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health. 2001;91:46-7.
35. Rhodes T, Platt L, Maximova S, Koshkina E, Latishevskaya N, Hickman M, et al. Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study. Addiction. 2006;101:252-66.
36. Hagan H, Des Jarlais DC, Stern R, Lelutiu-Weinberger C, Scheinmann R, Strauss S, et al. HCV Synthesis Project: Preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy. 2007;18:341-51.
37. Roy E, Alary M, Morissette C, Leclerc P, Boudreau JF, Parent R, et al. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int J STD AIDS. 2007;18:23-7.
38. Xia X, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health. 2008;122:990-1003.
39. Dumchev KV, Soldyshev R, Qian HZ, Zezyulin OO, Chandler SD, Slobodyanyuk P, et al. HIV and hepatitis C virus infections among hanka injection drug users in central Ukraine: a cross-sectional survey. Harm Reduct J. 2009;6:23.
40. Rondinelli AJ, Ouellet LJ, Strathdee SA, Latka MH, Hudson SM, Hagan H, et al. Young adult injection drug users in the United States continue to practice HIV risk behaviors. Drug Alcohol Depend. 2009;104:167-74.
41. Lindenburg CE, Krol A, Smit C, Buster MC, Coutinho RA, Prins M. Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study. AIDS. 2006;20:1771-5.
42. Falster K, Kaldor JM, Maher L, Collaboration of Australian Needle and Syringe Programs. Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995-2004. J Urban Health. 2009;86:106-18.
43. Rhodes T, Treloar C. The social production of hepatitis C risk among injecting drug users: a qualitative synthesis. Addiction. 2008;103:1593-603.
44. Small W, Kerr T, Charette J, Schechter MT, Spittal PM. Impacts of intensified police activity on injection drug users: Evidence from an ethnographic investigation. Int J Drug Policy. 2006;17:85-95.
45. Shannon K, Rusch M, Shoveller J, Alexson D, Gibson K, Tyndall MW, et al. Mapping violence and policing as an environmental-structural barrier to health service and syringe availability among substance-using women in street-level sex work. Int J Drug Policy. 2008;19:140-7.